Deal Watch: Sanofi To Tap Owkin’s AI, Machine Learning In Oncology
Executive Summary
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
You may also be interested in...
Former Meta Exec: ‘Culture Is The Greatest Challenge To Benefiting From GenAI'
To Jerome Pesenti, the biggest hurdle to integrating generative artificial intelligence into the biopharma industry is accepting that data often knows better than humans.
Ex-Sanofi Partnering Chief Wants AI Start-Up Owkin To Be Industry Leader
Having led $30bn of acquisitions of companies at Sanofi, the new challenge for its former global head of partnering is to help make Owkin, “the most disruptive AI biotech company in the world,” he tells Scrip.
Finance Watch: VC Mega-Rounds Surge Again, Led By Acelyrin’s $300m Series C
Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals.